Two preclinical biotechs riding the IPO wave this week look to raise $466M-plus

Two preclinical biotechs riding the IPO wave this week look to raise $466M-plus

Source: 
Endpoints
snippet: 

→ These days, there’s virtually no raise too big for biotech. Case in point: 2 looming IPOs where the executive team is sketching out some mega-money that can fuel their operations for some time. Avidity Biosciences, which has a preclinical program for myotonic dystrophy type 1, believes it can gin up to $248 million or more now, based on the high end of their range.